Low-Dose MTX: Good Enough Even in Poor Prognosis RA?

Low-Dose MTX: Good Enough Even in Poor Prognosis RA?

Half of patients with rheumatoid arthritis (RA) considered to have a poor prognosis by European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria exhibited structural remission over 3 years with only low-dose

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.